Posts by Fred Schwaller

Chronic pain and substance use disorders.

Chronic Pain and Substance Use Disorders Have Shared Genetics

A new study includes data from more than 800,000 people with chronic pain, with lessons for the migraine field, too.
Retinal vasculature

Looking Migraine in the Eye

A non-invasive imaging tool reveals changes in the retinal microvasculature during migraine. The approach could help researchers better understand the pathophysiology of the condition and perhaps be of clinical use, too.
Environmental irritants, migraine, and TRPA1

Environmental Chemicals Can Trigger Migraine Signaling

A proof-of-concept study in mice shows that pesticides and pollutants activate migraine signaling pathways via the ion channel TRPA1. It’s unclear if the findings relate to migraine in people.

Meeting the Challenge of Cluster Headache: A Conversation with Andrea Carmine Belin

In this Migraine Science Collaborative interview, Andrea Carmine Belin chats about her career, the clinical problem of cluster headache, and recent research that is driving the understanding of cluster headache forward.
Anti-prolactin antibody for migraine and pain

A Novel Prolactin Antibody Prevents Pain Behaviors in Female Mice

The new approach paves the way for a better understanding of prolactin in female-predominant conditions, including migraine and pain disorders. But targeting prolactin as a potential treatment approach in people faces significant challenges.
migraine aura

Does Aura Really Initiate Migraine Attacks? Challenging the Conventional Wisdom

Neuroimaging findings from a single patient suggest that aura may be an epiphenomenon, with no causal role in the onset of an attack.

P2X7 Signaling Contributes to Meningeal Sensitization

Researchers provide a new explanation for how cortical spreading depression affects afferent nociceptive neurons in the meninges.
Neuroimmune signaling in migraine.

A Neuroimmune Signaling Pathway Drives Chronic Headache

A new study in mice finds that CCL2-CCR2 signaling in macrophages and T cells sensitizes trigeminal ganglion neurons, driving chronic headache in migraine models. With synergistic effects on CGRP, the pathway could be a new therapeutic target for migraine.
Galcanezumab, triggers, and premonitory symptoms.

Does CGRP Inhibition Quiet the “Migraine Brain”?

Three months of galcanezumab treatment reduced the incidence of premonitory symptoms and number of triggers followed by headache, even in patients classified as “non-responders” to the drug.
Fred Schwaller

Fred Schwaller is a science writer and communicator based in Berlin, Germany. Fred spent a decade in pain research during his doctoral degree at University College London, UK, and his postdoc at the Max Delbrück Centre in Berlin, Germany. After transferring to science communication in 2020, he has been writing and podcasting about life sciences and medicine, specializing in somatosensation and pain. Follow him on Twitter @SchwallerFred.